PROCEPT BioRobotics makes the AquaBeam, a surgical robot that uses a high-pressure water jet to remove prostate tissue—think of it as a GPS-guided power washer for urology.
Revenue comes from selling AquaBeam systems and their single-use handpieces; gross margin is 63.74%, but the company is unprofitable, losing USD 0.10B on USD 0.31B revenue in 2025.
The AquaBeam's FDA-cleared water-jet ablation is a unique, patented approach that Intuitive Surgical and Medtronic haven't replicated, but the moat is eroding as Boston Scientific and Olympus push competing minimally invasive BPH tools.

Key events, in time order
DJS Law Group files class action alleging securities law violations, affecting investor rights.
Management to present and host investor meetings on Sept 15 in NYC, routine roadshow
None yet
None yet
Procept BioRobotics is a significant holding in a portfolio outperforming the S&P 500, indicating a positive outlook on the company's performance.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice